产品详情
产品名称p21 (phospho-Thr145) Polyclonal Antibody
来源种属Rabbit
克隆性Polyclonal
纯化The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
应用WB,IHC-p,IF(paraffin section),ELISA
种属反应性Human;Mouse;Rat
特异性Phospho-p21 (T145) Polyclonal Antibody detects endogenous levels of p21 protein only when phosphorylated at T145.
免疫原描述The antiserum was produced against synthesized peptide derived from human p21 Cip1 around the phosphorylation site of Thr145. AA range:111-160
标记Unconjugated
别名CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinase inhibitor 1; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; MDA-6; p21
数据库入口号Swiss Prot:P38936
GeneID:1026
Uniprot
P38936
计算分子量18kd
浓度1 mg/ml
配方Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
保存-20˚C/1
应用详情
Western Blot: 1/500 - 1/2000.
Immunohistochemistry: 1/100 - 1/300.
ELISA: 1/10000. Not yet tested in other applications.
cyclin dependent kinase inhibitor 1A(CDKN1A) Homo sapiens This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lac
如果您使用该产品13652发表了文章，请通知我们，让我们可以引用您的文献。
et al,Hybrid-Ligand Metal–Organic Frameworks Enabling Radio–Radiodynamic–Chemodynamic Therapy Primes Checkpoint Blockade Immunotherapy in Hypoxic Tumors
, (2025),
PMID:
40802503
Yes
